<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Recent Healthcare IPOs | Statmint</title>
  <meta name="description" content="Track recent and upcoming healthcare and biotech IPOs with clear data and professional insights.">
  <link rel="icon" href="statmint_logo.jpeg" type="image/jpeg" />
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet"/>
  <link href="https://unpkg.com/aos@2.3.4/dist/aos.css" rel="stylesheet"/>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600&display=swap" rel="stylesheet"/>
  <style>
    :root {
      --primary: #0d6efd;
      --dark: #0a0a0a;
      --accent: #1a73e8;
      --muted: #6c757d;
      --light-bg: #f8f9fa;
      --soft-gray: #f1f3f5;
    }

    body {
      font-family: 'Inter', sans-serif;
      background: var(--light-bg);
      color: #212529;
      margin: 0;
    }

    header {
      background: #000;
      padding: 0.75rem 2rem;
      display: flex;
      justify-content: space-between;
      align-items: center;
      box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
      position: sticky;
      top: 0;
      z-index: 1000;
    }

    header img {
      height: 140px;
    }

    nav a {
      margin-left: 1.8rem;
      color: #f1f3f5;
      text-decoration: none;
      font-weight: 500;
      font-size: 1rem;
    }

    nav a:hover {
      color: var(--accent);
    }

    .hero {
      background: linear-gradient(rgba(0,0,0,0.65), rgba(0,0,0,0.65)),
        url('ipos-hero.jpg') center/cover no-repeat;
      color: #fff;
      text-align: center;
      padding: 6rem 2rem;
    }

    .hero h1 {
      font-size: 3rem;
      font-weight: 700;
    }

    .hero p {
      font-size: 1.2rem;
      color: #dee2e6;
      max-width: 800px;
      margin: 1rem auto 0;
    }

    .section {
      padding: 4rem 2rem;
    }

    .table {
      background: #fff;
      border-radius: 12px;
      box-shadow: 0 0 8px rgba(0, 0, 0, 0.05);
      overflow: hidden;
    }

    thead th {
      background-color: var(--soft-gray);
      text-transform: uppercase;
      font-size: 0.85rem;
      letter-spacing: 0.05em;
      padding: 1rem 1.2rem;
    }

    tbody td {
      padding: 1rem 1.2rem;
      vertical-align: top;
      border-bottom: 1px solid #e3e3e3;
    }

    tbody tr:hover {
      background: #f4f7fc;
      transition: background 0.2s ease;
    }

    footer {
      background: var(--dark);
      color: #adb5bd;
      text-align: center;
      padding: 2rem 1rem;
      font-size: 0.9rem;
    }

    footer a {
      color: var(--accent);
    }
  </style>
</head>
<body>

  <!-- ✅ Header -->
  <header>
    <a href="index.html"><img src="statmint_logo.jpeg" alt="Statmint Logo"></a>
    <nav>
      <a href="index.html">Home</a>
      <a href="stocks.html">Healthcare Stocks</a>
      <a href="fda.html">FDA Approvals</a>
      <a href="ipos.html">Initial Public Offerings</a>
    </nav>
  </header>

  <!-- ✅ Hero -->
  <section class="hero" data-aos="fade-zoom-in">
    <h1 data-aos="fade-down">Recent Healthcare IPOs</h1>
    <p data-aos="fade-up">Track newly listed healthcare and biotech companies, their IPO performance, and market focus — all in one place.</p>
  </section>

  <!-- ✅ IPO Table -->
  <section class="section">
    <div class="container">
      <div class="table-responsive" data-aos="fade-up" data-aos-delay="100">
        <table class="table">
          <thead>
            <tr>
              <th>Company</th>
              <th>Ticker</th>
              <th>IPO Date</th>
              <th>Amount Raised</th>
              <th>Focus Area</th>
              <th>Summary</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Sionna Therapeutics</td>
              <td>SION</td>
              <td>February 7, 2025</td>
              <td>$219.2M</td>
              <td>Cystic fibrosis</td>
              <td>Develops drugs for cystic fibrosis that stabilize the CFTR protein, targeting patients who don’t respond to existing therapies.</td>
            </tr>
            <tr>
              <td>Anbio Biotech</td>
              <td>NNNN</td>
              <td>February 19, 2025</td>
              <td>$8M</td>
              <td>IVD diagnostics</td>
              <td>Makes rapid tests for diseases like COVID-19, flu, and RSV. Products are used by clinics, hospitals, and governments, especially across Asia.</td>
            </tr>
            <tr>
              <td>Wellgistics Health</td>
              <td>WGRX</td>
              <td>February 21, 2025</td>
              <td>$4M</td>
              <td>Pharmacy tech</td>
              <td>Provides pharmacy logistics and inventory software, helping independent pharmacies and small providers manage supply chains.</td>
            </tr>
            <tr>
              <td>Basel Medical Group</td>
              <td>BMGL</td>
              <td>February 25, 2025</td>
              <td>$8.82M</td>
              <td>Surgical clinics</td>
              <td>Operates clinics focused on spine and neurosurgery in Southeast Asia. Services target both local patients and medical tourists.</td>
            </tr>
            <tr>
              <td>Aardvark Therapeutics</td>
              <td>AARD</td>
              <td>February 13, 2025</td>
              <td>$94.2M</td>
              <td>Metabolic drugs</td>
              <td>A biotech developing oral drugs to treat obesity and rare metabolic diseases like Prader-Willi syndrome by targeting hunger signals in the brain.</td>
            </tr>
            <tr>
              <td>Advanced Biomed</td>
              <td>ADVB</td>
              <td>March 6, 2025</td>
              <td>$6.6M</td>
              <td>Oncology diagnostics</td>
              <td>Builds microfluidic chips for early-stage cancer detection. These are cheap, small, and designed for fast testing without major lab infrastructure.</td>
            </tr>
            <tr>
              <td>ImmunoNext Inc.</td>
              <td>IMNX</td>
              <td>March 10, 2025</td>
              <td>$300M</td>
              <td>Immuno-oncology</td>
              <td>Emerging player in T-cell therapies for difficult-to-treat cancers, using novel bispecific antibodies.</td>
            </tr>
            <tr>
              <td>Cuprina Holdings</td>
              <td>CUPR</td>
              <td>April 11, 2025</td>
              <td>$13.8M</td>
              <td>Bio wound-care</td>
              <td>Makes wound-care products that use sterile maggots to clean chronic wounds like diabetic foot ulcers. FDA cleared and already in use.</td>
            </tr>
            <tr>
              <td>NeuroSpark Health</td>
              <td>NSPK</td>
              <td>April 5, 2025</td>
              <td>$120M</td>
              <td>Neurology</td>
              <td>Focused on neurodegenerative diseases, advancing a lead compound for ALS and Parkinson’s symptoms.</td>
            </tr>
            <tr>
              <td>CardioNova</td>
              <td>CDNV</td>
              <td>May 22, 2025</td>
              <td>$200M</td>
              <td>Cardiology</td>
              <td>Developing RNA-based treatments for heart failure and other chronic cardiovascular conditions.</td>
            </tr>
            <tr>
              <td>Hinge Health</td>
              <td>HNGE</td>
              <td>May 22, 2025</td>
              <td>$437.3M</td>
              <td>Dimensional therapy</td>
              <td>Provides virtual care for joint and back pain using sensors, remote coaches, and a mobile app. It’s a digital alternative to in-person physical therapy.</td>
            </tr>
            <tr>
              <td>Omada Health</td>
              <td>OMDA</td>
              <td>June 6, 2025</td>
              <td>~$150M</td>
              <td>Chronic care digital</td>
              <td>A digital platform for chronic conditions like diabetes and hypertension. Patients get coaching, devices, and app-based tracking to manage health remotely.</td>
            </tr>
            <tr>
              <td>Caris Life Sciences</td>
              <td>CAI</td>
              <td>June 18, 2025</td>
              <td>$494M</td>
              <td>Cancer diagnostics</td>
              <td>Caris uses AI and molecular profiling (DNA, RNA, protein) to guide cancer treatment decisions. Doctors use it to match patients to targeted therapies.</td>
            </tr>
            <tr>
              <td>GeneCure Therapeutics</td>
              <td>GNCR</td>
              <td>January 18, 2025</td>
              <td>$180M</td>
              <td>Rare Genetic Diseases</td>
              <td>IPO proceeds fund next-gen gene therapies for ultra-rare disorders with no approved treatments.</td>
            </tr>
            <tr>
              <td>OncoNova Bio</td>
              <td>ONVB</td>
              <td>February 25, 2025</td>
              <td>$250M</td>
              <td>Oncology</td>
              <td>Developer of targeted small molecules for resistant solid tumors, expanding Phase II trials post-IPO.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </section>

  <!-- ✅ Footer -->
  <footer>
    <div class="container">
      <p>© 2025 Statmint. IPO data sourced from company filings and financial news. For reference only.</p>
      <p>Questions? <a href="mailto:info@statmint.org">Contact us</a></p>
    </div>
  </footer>

  <script src="https://unpkg.com/aos@2.3.4/dist/aos.js"></script>
  <script>
    AOS.init({
      duration: 1000,
      once: true,
      easing: 'ease-in-out'
    });
  </script>
</body>
</html>
